Breaking News

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

Genius AI Detection Receives FDA Clearance – New Deep Learning-based Software Designed to Help Radiologists Detect Subtle Potential Cancers in Breast Tomosynthesis Images

This new technology, represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius® 3D Mammography™ exam.

Passio Pump Drainage System Granted 510(k) for Additional Indication for Home Use

The Passio Pump Drainage System consists of the Passio Catheter, a Handheld Control Unit (pump) and a Disposable Collection Kit, which includes a redressing kit, for drainage of recurrent and symptomatic pleural effusion.

Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

Boston Scientific notes SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases.

Gayle Sheppard is Appointed to the NovaSignal Advisory Board

September 11, 2020

Gayle Sheppard has been appointed to the NovaSignal advisory board.

Gayle Sheppard is a global technology entrepreneur and leader with a proven track record of scaling small- and medium-sized companies to a market-leading position. As Chairman and CEO of Saffron Technology, Inc., a predictive reasoning solution for enterprise decision making, Sheppard successfully grew the business to $20M in revenue and an acquisition in 2015 by Intel, where she continued to lead the business through 2018. Currently, Sheppard serves as Corporate Vice President of Azure Data at Microsoft, where she is responsible for the vision, strategy, and long-range P&L for growing Microsoft’s Cloud Services with customers who are implementing multiyear digital innovation and modernization strategies.

Earlier in her career, Sheppard held the role of Vice President and Managing Director at PeopleSoft and served as CEO and President of MarketMile (now part of Rearden Commerce), where she led the development and launch of a software-as-a-service e-procurement business for American Express.

“Gayle’s global experience in successfully building companies – specifically those fueled by artificial intelligence – will be invaluable as we scale to meet the growing demand and extend the reach and impact of our solutions worldwide. I personally look forward to benefiting from her relevant expertise and advice,” said Diane Bryant, Chairman and CEO of NovaSignal.

“I am honored and excited to join such a strong team of technology leaders with the vision of ending brain disease through cerebral blood flow analysis,” said Sheppard. “With Saffron I built a team and business that solved real world problems and delivered shareholder value. To work with NovaSignal in achieving industry leadership is a great honor.”

Sheppard is a graduate of the University of South Florida, where she received a B.S. in Business Administration with a focus in operations research and management science.

Latest Posts

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.